PMID- 24009295 OWN - NLM STAT- MEDLINE DCOM- 20141028 LR - 20220311 IS - 1460-2385 (Electronic) IS - 0931-0509 (Print) IS - 0931-0509 (Linking) VI - 28 IP - 11 DP - 2013 Nov TI - Sensitization from transfusion in patients awaiting primary kidney transplant. PG - 2908-18 LID - 10.1093/ndt/gft362 [doi] AB - BACKGROUND: Sensitization to human leukocyte antigen (HLA) from red blood cell (RBC) transfusion is poorly quantified and is based on outdated, insensitive methods. The objective was to evaluate the effect of transfusion on the breadth, magnitude and specificity of HLA antibody formation using sensitive and specific methods. METHODS: Transfusion, demographic and clinical data from the US Renal Data System were obtained for patients on dialysis awaiting primary kidney transplant who had >/= 2 HLA antibody measurements using the Luminex single-antigen bead assay. One cohort included patients with a transfusion (n = 50) between two antibody measurements matched with up to four nontransfused patients (n = 155) by age, sex, race and vintage (time on dialysis). A second crossover cohort (n = 25) included patients with multiple antibody measurements before and after transfusion. We studied changes in HLA antibody mean fluorescence intensity (MFI) and calculated panel reactive antibody (cPRA). RESULTS: In the matched cohort, 10 of 50 (20%) transfused versus 6 of 155 (4%) nontransfused patients had a >/= 10 HLA antibodies increase of >3000 MFI (P = 0.0006); 6 of 50 (12%) transfused patients had a >/= 30 antibodies increase (P = 0.0007). In the crossover cohort, the number of HLA antibodies increasing >1000 and >3000 MFI was higher in the transfused versus the control period, P = 0.03 and P = 0.008, respectively. Using a >/= 3000 MFI threshold, cPRA significantly increased in both matched (P = 0.01) and crossover (P = 0.002) transfused patients. CONCLUSIONS: Among prospective primary kidney transplant recipients, RBC transfusion results in clinically significant increases in HLA antibody strength and breadth, which adversely affect the opportunity for future transplant. FAU - Yabu, Julie M AU - Yabu JM AD - Division of Nephrology, Department of Medicine, Stanford University, Stanford, CA, USA. FAU - Anderson, Matthew W AU - Anderson MW FAU - Kim, Deborah AU - Kim D FAU - Bradbury, Brian D AU - Bradbury BD FAU - Lou, Calvin D AU - Lou CD FAU - Petersen, Jeffrey AU - Petersen J FAU - Rossert, Jerome AU - Rossert J FAU - Chertow, Glenn M AU - Chertow GM FAU - Tyan, Dolly B AU - Tyan DB LA - eng GR - K23AI104401/AI/NIAID NIH HHS/United States GR - K23 AI104401/AI/NIAID NIH HHS/United States GR - K24DK54488/DK/NIDDK NIH HHS/United States GR - R37 DK054488/DK/NIDDK NIH HHS/United States GR - R01 DK054488/DK/NIDDK NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20130905 PL - England TA - Nephrol Dial Transplant JT - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association JID - 8706402 RN - 0 (Antibodies) RN - 0 (HLA Antigens) SB - IM MH - Antibodies/*blood/immunology MH - Antibody Formation/*immunology MH - *Blood Transfusion MH - Cross-Over Studies MH - Female MH - HLA Antigens/*immunology MH - Humans MH - Kidney Failure, Chronic/blood/*immunology/surgery MH - *Kidney Transplantation MH - Male MH - Middle Aged MH - Prospective Studies MH - Renal Dialysis MH - Waiting Lists PMC - PMC3811060 OTO - NOTNLM OT - HLA antibody OT - calculated panel reactive antibody OT - kidney transplantation OT - sensitization OT - transfusion EDAT- 2013/09/07 06:00 MHDA- 2014/10/29 06:00 PMCR- 2014/11/01 CRDT- 2013/09/07 06:00 PHST- 2013/09/07 06:00 [entrez] PHST- 2013/09/07 06:00 [pubmed] PHST- 2014/10/29 06:00 [medline] PHST- 2014/11/01 00:00 [pmc-release] AID - gft362 [pii] AID - 10.1093/ndt/gft362 [doi] PST - ppublish SO - Nephrol Dial Transplant. 2013 Nov;28(11):2908-18. doi: 10.1093/ndt/gft362. Epub 2013 Sep 5.